{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:19:42Z","timestamp":1793387982849,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T00:00:00Z","timestamp":1386288000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s12185-013-1479-5","type":"journal-article","created":{"date-parts":[[2013,12,5]],"date-time":"2013-12-05T09:07:53Z","timestamp":1386234473000},"page":"361-371","source":"Crossref","is-referenced-by-count":93,"title":["Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies"],"prefix":"10.1007","volume":"99","author":[{"given":"Marco L.","family":"Davila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana C. G.","family":"Bouhassira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hollie J.","family":"Pegram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renier","family":"Brentjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,12,6]]},"reference":[{"key":"1479_CR1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrc971","volume":"3","author":"M Sadelain","year":"2003","unstructured":"Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003;3:35\u201345.","journal-title":"Nat Rev Cancer"},{"key":"1479_CR2","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.4161\/onci.22524","volume":"1","author":"ML Davila","year":"2012","unstructured":"Davila ML, Brentjens R, Wang X, Riviere I, Sadelain M. How do CARs work?: early insights from recent clinical studies targeting CD19. Oncoimmunology. 2012;1:1577\u201383.","journal-title":"Oncoimmunology"},{"key":"1479_CR3","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3:388\u201398.","journal-title":"Cancer Discov"},{"key":"1479_CR4","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","volume":"121","author":"B Savoldo","year":"2011","unstructured":"Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011;121:1822\u20136.","journal-title":"J Clin Invest"},{"key":"1479_CR5","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.bbmt.2010.03.014","volume":"16","author":"MC Jensen","year":"2010","unstructured":"Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR, et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20\/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant. 2010;16:1245\u201356.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1479_CR6","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","volume":"116","author":"JN Kochenderfer","year":"2010","unstructured":"Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116:4099\u2013102.","journal-title":"Blood"},{"key":"1479_CR7","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","volume":"119","author":"JN Kochenderfer","year":"2012","unstructured":"Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119:2709\u201320.","journal-title":"Blood"},{"key":"1479_CR8","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3:95ra73.","journal-title":"Sci Transl Med"},{"key":"1479_CR9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725\u201333.","journal-title":"N Engl J Med"},{"key":"1479_CR10","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","volume":"118","author":"RJ Brentjens","year":"2011","unstructured":"Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118:4817\u201328.","journal-title":"Blood"},{"key":"1479_CR11","doi-asserted-by":"crossref","first-page":"177ra138","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5:177ra138.","journal-title":"Sci Transl Med"},{"key":"1479_CR12","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509\u201318.","journal-title":"N Engl J Med"},{"key":"1479_CR13","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1084\/jem.178.3.951","volume":"178","author":"YS Li","year":"1993","unstructured":"Li YS, Hayakawa K, Hardy RR. The regulated expression of B lineage associated genes during B cell differentiation in bone marrow and fetal liver. J Exp Med. 1993;178:951\u201360.","journal-title":"J Exp Med"},{"key":"1479_CR14","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S1074-7613(00)80268-X","volume":"5","author":"YS Li","year":"1996","unstructured":"Li YS, Wasserman R, Hayakawa K, Hardy RR. Identification of the earliest B lineage stage in mouse bone marrow. Immunity. 1996;5:527\u201335.","journal-title":"Immunity"},{"key":"1479_CR15","doi-asserted-by":"crossref","first-page":"10995","DOI":"10.1158\/0008-5472.CAN-06-0160","volume":"66","author":"CM Kowolik","year":"2006","unstructured":"Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 2006;66:10995\u20131004.","journal-title":"Cancer Res"},{"key":"1479_CR16","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1038\/sj.leu.2404366","volume":"20","author":"A Loskog","year":"2006","unstructured":"Loskog A, Giandomenico V, Rossig C, Pule M, Dotti G, Brenner MK. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia. 2006;20:1819\u201328.","journal-title":"Leukemia"},{"key":"1479_CR17","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-07-0674","volume":"13","author":"RJ Brentjens","year":"2007","unstructured":"Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2007;13:5426\u201335.","journal-title":"Clin Cancer Res"},{"key":"1479_CR18","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","volume":"119","author":"HJ Pegram","year":"2012","unstructured":"Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012;119:4133\u201341.","journal-title":"Blood"},{"key":"1479_CR19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/CJI.0b013e318194a921","volume":"32","author":"EJ Cheadle","year":"2009","unstructured":"Cheadle EJ, Hawkins RE, Batha H, Rothwell DG, Ashton G, Gilham DE. Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4+ and CD8+ T Cells. J Immunother. 2009;32:207\u201318.","journal-title":"J Immunother"},{"key":"1479_CR20","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.4049\/jimmunol.0901440","volume":"184","author":"EJ Cheadle","year":"2010","unstructured":"Cheadle EJ, Hawkins RE, Batha H, O\u2019Neill AL, Dovedi SJ, Gilham DE. Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells. J Immunol. 2010;184:1885\u201396.","journal-title":"J Immunol"},{"key":"1479_CR21","doi-asserted-by":"crossref","first-page":"e61338","DOI":"10.1371\/journal.pone.0061338","volume":"8","author":"ML Davila","year":"2013","unstructured":"Davila ML, Kloss CC, Gunset G, Sadelain M. CD19 CAR-targeted T cells induce long-term remission and B cell aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS One. 2013;8:e61338.","journal-title":"PLoS One"},{"key":"1479_CR22","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","volume":"109","author":"AK Fielding","year":"2007","unstructured":"Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study. Blood. 2007;109:944\u201350.","journal-title":"Blood"},{"key":"1479_CR23","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2012.46.2309","volume":"31","author":"S O\u2019Brien","year":"2013","unstructured":"O\u2019Brien S, Schiller G, Lister J, Damon L, Goldberg S, Aulitzky W, et al. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol. 2013;31:676\u201383.","journal-title":"J Clin Oncol"},{"key":"1479_CR24","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1182\/blood-2012-07-441030","volume":"120","author":"MS Topp","year":"2012","unstructured":"Topp MS, Gokbuget N, Zugmaier G, Degenhard E, Goebeler ME, Klinger M, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012;120:5185\u20137.","journal-title":"Blood"},{"key":"1479_CR25","first-page":"717","volume":"120","author":"DL Porter","year":"2012","unstructured":"Porter DL, Grupp SA, Kalos M, Loren AW, Lledo L, Gilmore J, et al. Chimeric antigen receptor T cells directed against CD19 induce durable responses and transient cytokine release syndrome in relapsed, refractory CLL and ALL. ASH Annu Meet Abstr. 2012;120:717.","journal-title":"ASH Annu Meet Abstr"},{"key":"1479_CR26","first-page":"1797","volume":"120","author":"JH Park","year":"2012","unstructured":"Park JH, Riviere I, Wang X, Stefanski J, He Q, Taylor C, et al. Impact of the conditioning chemotherapy on outcomes in adoptive T cell therapy: results from a phase I clinical trial of autologous CD19-targeted T cells for patients with relapsed CLL. ASH Annu Meet Abstr. 2012;120:1797.","journal-title":"ASH Annu Meet Abstr"},{"key":"1479_CR27","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/mt.2010.2","volume":"18","author":"PB Hackett","year":"2010","unstructured":"Hackett PB, Largaespada DA, Cooper LJ. A transposon and transposase system for human application. Mol Ther. 2010;18:674\u201383.","journal-title":"Mol Ther"},{"key":"1479_CR28","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nm0403-367","volume":"9","author":"C Bonini","year":"2003","unstructured":"Bonini C, Grez M, Traversari C, Ciceri F, Marktel S, Ferrari G, et al. Safety of retroviral gene marking with a truncated NGF receptor. Nat Med. 2003;9:367\u20139.","journal-title":"Nat Med"},{"key":"1479_CR29","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/mt.2009.210","volume":"18","author":"XS Zhong","year":"2010","unstructured":"Zhong XS, Matsushita M, Plotkin J, Riviere I, Sadelain M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase\/AKT\/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther. 2010;18:413\u201320.","journal-title":"Mol Ther"},{"key":"1479_CR30","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(09)70074-9","volume":"10","author":"F Ciceri","year":"2009","unstructured":"Ciceri F, Bonini C, Stanghellini MT, Bondanza A, Traversari C, Salomoni M, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol. 2009;10:489\u2013500.","journal-title":"Lancet Oncol"},{"key":"1479_CR31","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.bbmt.2007.04.005","volume":"13","author":"SK Tey","year":"2007","unstructured":"Tey SK, Dotti G, Rooney CM, Heslop HE, Brenner MK. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:913\u201324.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1479_CR32","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Stasi Di","year":"2011","unstructured":"Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365:1673\u201383.","journal-title":"N Engl J Med"},{"key":"1479_CR33","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1182\/blood-2010-10-311845","volume":"117","author":"GM Giordano Attianese","year":"2011","unstructured":"Giordano Attianese GM, Marin V, Hoyos V, Savoldo B, Pizzitola I, Tettamanti S, et al. In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor. Blood. 2011;117:4736\u201345.","journal-title":"Blood"},{"key":"1479_CR34","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/76243","volume":"6","author":"A Trojan","year":"2000","unstructured":"Trojan A, Schultze JL, Witzens M, Vonderheide RH, Ladetto M, Donovan JW, et al. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med. 2000;6:667\u201372.","journal-title":"Nat Med"},{"key":"1479_CR35","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1182\/blood-2006-04-017061","volume":"108","author":"J Vera","year":"2006","unstructured":"Vera J, Savoldo B, Vigouroux S, Biagi E, Pule M, Rossig C, et al. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood. 2006;108:3890\u20137.","journal-title":"Blood"},{"key":"1479_CR36","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2010-05-283309","volume":"116","author":"M Hudecek","year":"2010","unstructured":"Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood. 2010;116:4532\u201341.","journal-title":"Blood"},{"key":"1479_CR37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11\u201330.","journal-title":"CA Cancer J Clin"},{"key":"1479_CR38","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516\u201320.","journal-title":"Blood"},{"key":"1479_CR39","doi-asserted-by":"crossref","first-page":"4610","DOI":"10.1182\/blood.V99.12.4610","volume":"99","author":"R Bellucci","year":"2002","unstructured":"Bellucci R, Alyea EP, Weller E, Chillemi A, Hochberg E, Wu CJ, et al. Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. Blood. 2002;99:4610\u20137.","journal-title":"Blood"},{"key":"1479_CR40","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1309\/74R4TB90BUWH27JX","volume":"121","author":"P Lin","year":"2004","unstructured":"Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004;121:482\u20138.","journal-title":"Am J Clin Pathol"},{"key":"1479_CR41","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/leu.2011.205","volume":"26","author":"K Mihara","year":"2012","unstructured":"Mihara K, Bhattacharyya J, Kitanaka A, Yanagihara K, Kubo T, Takei Y, et al. T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells. Leukemia. 2012;26:365\u20137.","journal-title":"Leukemia"},{"key":"1479_CR42","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1158\/1538-7445.AM2012-3499","volume":"72","author":"R Benjamin","year":"2012","unstructured":"Benjamin R, Condomines M, Gunset G, Sadelain M. CD56 targeted chimeric antigen receptors for immunotherapy of multiple myeloma. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research. \u00a0Cancer Res. 2012;72:3499.","journal-title":"Cancer Res"},{"key":"1479_CR43","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/gt.2010.21","volume":"17","author":"S Peinert","year":"2010","unstructured":"Peinert S, Prince HM, Guru PM, Kershaw MH, Smyth MJ, Trapani JA, et al. Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. Gene Ther. 2010;17:678\u201386.","journal-title":"Gene Ther"},{"key":"1479_CR44","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","volume":"19","author":"RO Carpenter","year":"2013","unstructured":"Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19:2048\u201360.","journal-title":"Clin Cancer Res"},{"key":"1479_CR45","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/gt.2012.48","volume":"20","author":"PC Schuberth","year":"2013","unstructured":"Schuberth PC, Jakka G, Jensen SM, Wadle A, Gautschi F, Haley D, et al. Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma. Gene Ther. 2013;20:386\u201395.","journal-title":"Gene Ther"},{"key":"1479_CR46","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.3324\/haematol.2010.026310","volume":"95","author":"V Marin","year":"2010","unstructured":"Marin V, Pizzitola I, Agostoni V, Attianese GM, Finney H, Lawson A, et al. Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors. Haematologica. 2010;95:2144\u201352.","journal-title":"Haematologica"},{"key":"1479_CR47","doi-asserted-by":"crossref","first-page":"683065","DOI":"10.1155\/2012\/683065","volume":"2012","author":"A Dutour","year":"2012","unstructured":"Dutour A, Marin V, Pizzitola I, Valsesia-Wittmann S, Lee D, Yvon E, et al. In vitro and in vivo antitumor effect of anti-CD33 chimeric receptor-expressing EBV-CTL against CD33 acute myeloid leukemia. Adv Hematol. 2012;2012:683065.","journal-title":"Adv Hematol"},{"key":"1479_CR48","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/bjh.12282","volume":"161","author":"S Tettamanti","year":"2013","unstructured":"Tettamanti S, Marin V, Pizzitola I, Magnani CF, Giordano Attianese GM, Cribioli E, et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol. 2013;161:389\u2013401.","journal-title":"Br J Haematol"},{"key":"1479_CR49","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/mt.2013.154","volume":"21","author":"DS Ritchie","year":"2013","unstructured":"Ritchie DS, Neeson PJ, Khot A, Peinert S, Tai T, Tainton K, et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther. 2013;21:2122\u20139.","journal-title":"Mol Ther"},{"key":"1479_CR50","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/(SICI)1097-0215(19970926)73:1<50::AID-IJC9>3.0.CO;2-0","volume":"73","author":"S Zhang","year":"1997","unstructured":"Zhang S, Zhang HS, Cordon-Cardo C, Reuter VE, Singhal AK, Lloyd KO, et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: II Blood group-related antigens. Int J Cancer. 1997;73:50\u20136.","journal-title":"Int J Cancer"},{"key":"1479_CR51","doi-asserted-by":"crossref","unstructured":"O\u2019Hear C, Inaba H, Pounds S, Shi L, Dahl G, Bowman WP, et al. Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. Cancer 2013.","DOI":"10.1002\/cncr.28334"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-013-1479-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-013-1479-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-013-1479-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T05:11:15Z","timestamp":1559452275000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-013-1479-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,6]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["1479"],"URL":"https:\/\/doi.org\/10.1007\/s12185-013-1479-5","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,6]]}}}